secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0000950170-23-063369
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo Q3 2023 net loss $6.3M; cash $19.1M; funding extends runway into Q4 2024
-------------------------------------------------------------------------------

- Net loss of $6.3M ($0.50 per share) vs $7.6M loss in Q3 2022; no revenue reported.
- Cash and equivalents $19.1M at Sept 30; raised $7M via public offering and warrant exercises, with potential additional $9.2M.
- R&D expenses $3.9M (down $0.6M); G&A $2.7M (down $0.6M) year-over-year.
- ALG.APV-527 Phase 1 dose-escalation trial for solid tumors continues enrolling patients; APVO436 Phase 2 planning ongoing.
- Cash runway expected into Q4 2024, allowing reach of clinical milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017023063369/0000950170-23-063369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017023063369/apvo-20231114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-063369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer